Senescence Syndrome: an Extensive Literature Review on Environmental, Digital, and Molecular Drivers of Early-onset Somatic Aging

Accelerated Cellular Senescence Syndrome (ACSS), a rare somatic disorder that defies traditional gerontological paradigms, disproportionately affects young persons between the ages of 20 and 40. Unlike classic chronological aging caused by random metabolic attrition, ACSS is produced by the remarkable convergence of modern environmental mutagens, such as ingested micro/nano plastics, prolonged anthropogenic stress, and persistent high-energy visible blue light. ACSS a rare somatic disorder that defies traditional gerontological paradigms, disproportionately affects young persons between the ages of 20 and 40. Unlike classic chronological aging caused by random metabolic attrition, ACSS is produced by the remarkable convergence of modern environmental mutagens, such as ingested micro/nano plastics, prolonged anthropogenic stress, and persistent high-energy visible blue light. Cell-cycle checkpoints are prematurely stopped as a result of the persistent upregulation of the p16INK4a and p53/p21CIP1 molecular pathways. This review carefully maps the molecular underpinnings of ACSS, critically evaluates existing management strategies, and provides a comprehensive structural differential diagnosis matrix against traditional autoimmune diseases. Although first-generation senolytic treatments show great promise for removing senescent cell centers, systemic cytotoxicity and off-target tissue damage continue to impede their translation. In the end, a paradigm shift toward targeted biotechnology such as antibody-drug conjugates and microplastic-clearing mRNA lipid nanoparticles as well as international regulatory frameworks to reduce current digital and environmental toxicities are required to address this contemporary medical crisis.